Skip to content
Nephrogen logo

Nephrogen

Nephrogen is a YC Summer 2020 (S20) company. Based in New York, NY, USA. Team of 1.

  • Gene Therapy
  • CRISPR
  • Biotech

About Nephrogen

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Nephrogen develops gene therapies for kidney and pancreatic diseases, two tissue types that existing genetic medicines cannot reliably reach. Its NeFIND platform uses AI and high-throughput in vivo screening to design adeno-associated viral delivery vehicles with tissue-specific tropism, producing candidates that are far more efficient and less immunogenic than current options. The platform replaces manual, low-yield delivery vehicle discovery and unlocks therapeutic approaches for diseases that affect tens of millions of Americans and have no approved gene-based treatments.

Go-to-market

Nephrogen is a Stanford spinout advancing its pipeline through preclinical research, with the NeFIND platform positioned to support internal therapeutic programs targeting kidney and pancreatic diseases.

From the Y Combinator listing

How Nephrogen describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Curative gene therapies for kidney diseases

Nephrogen is a biotech company developing curative gene therapies for kidney and pancreatic diseases. Kidney disease affects 1 in 7 Americans (~50 million people), has no cure, and accounts for nearly 10% of the Medicare budget.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
New York, NY, USA
Team size
1
Status
Active
Stage
Early

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works